Loading patent…
AssigneeUniversity of Zurich
InventorsUwe ZANGEMEISTER-WITTKE, Claudio DI PAOLO, Dominique Christine TSCHUDI, Nicholas Ronald GLOVER, Dimitri Peter FITSIALOS
Estimating the term…
The present invention relates to methods for preventing or treating head and neck spuamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotixin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.
1-57. (canceled)
A kit for treating head and neck squamous cell carcinoma comprising an immunotoxin having an amino acid sequence of SEQ ID NO. 2, and instructions for use thereof.
A kit for treating bladder cancer comprising an immunotoxin having an amino acid sequence of SEQ ID NO. 2, and instructions for use thereof.
A method of treating a head and neck squamous cell carcinoma, the method comprising administering an effective amount of an immunotoxin in combination with a cancer therapeutic to a subject, wherein the immunotoxin comprises an amino acid of SEQ ID NO:2.
A method of treating bladder cancer, the method comprising administering an effective amount of an immunotoxin in combination with a cancer therapeutic to a subject, wherein the immunotoxin comprises an amino acid sequence of SEQ ID NO:2.
A method of treating bladder cancer comprising administering directly to the cancer site an effective amount of an immunotoxin of SEQ ID NO:
A method of treating head and neck cancer comprising administering directly to the cancer site an effective amount of an immunotoxin of SEQ ID NO:
Dependencies are inferred from the claim text.